The story
France’s June 2013 decree opened a route for authorised cannabis-containing medicines. Its exception depended on the pharmaceutical product holding a qualifying marketing authorisation.
Signed on 5 June and published on 7 June, Decree 2013-473 took effect on 8 June 2013. It added a third part to Public Health Code article R.5132-86, exempting specified operations involving pharmaceutical specialties authorised in France or through the European Union.
The listed operations included manufacture, transport, import, export, possession, supply, transfer, acquisition and use. Their scope was tied to those authorised medicines; the list was not a general permission to grow cannabis or obtain any cannabis product for treatment. Nor did the decree itself show that a medicine was stocked or available to patients.
Parrella’s contemporaneous overview describes the change broadly as approval of therapeutic cannabis. The original wording supports the narrower description used here. The history date records commencement, separately from signature and publication.[1][2]
Listed for context. No score change is recorded for France here.
References
- Légifrance — Decree 2013-473 of 5 June 2013, original textArticle 1; Journal officiel of 7 June 2013; commencement noticearchived
- Cannabis: non solo fumoBernardo Parrella · Stampa Alternativa · 2014 · Scenari per il nuovo millennio — I dinamismi del quadro globale
Checked. The date and the event were compared with a source that was read.